FY2025 Earnings Forecast for LXEO Issued By Chardan Capital

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) – Analysts at Chardan Capital cut their FY2025 earnings estimates for Lexeo Therapeutics in a research report issued on Tuesday, March 25th. Chardan Capital analyst G. Livshits now expects that the company will post earnings per share of ($3.10) for the year, down from their prior forecast of ($2.30). Chardan Capital currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($3.14) per share.

Other research analysts also recently issued reports about the company. HC Wainwright reaffirmed a “buy” rating and issued a $23.00 price target on shares of Lexeo Therapeutics in a research report on Wednesday. Royal Bank of Canada dropped their target price on shares of Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 25th. Finally, Leerink Partners reduced their price target on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating for the company in a report on Monday, March 24th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $22.80.

Lexeo Therapeutics Trading Down 0.2 %

Lexeo Therapeutics stock opened at $4.10 on Friday. Lexeo Therapeutics has a 52 week low of $2.32 and a 52 week high of $19.50. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.95 and a current ratio of 5.95. The firm has a market capitalization of $136.11 million, a PE ratio of -1.30 and a beta of 3.85. The business’s 50-day simple moving average is $4.05 and its 200-day simple moving average is $6.56.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its earnings results on Monday, March 24th. The company reported ($0.78) EPS for the quarter, topping the consensus estimate of ($0.87) by $0.09.

Institutional Investors Weigh In On Lexeo Therapeutics

A number of institutional investors have recently bought and sold shares of LXEO. Janus Henderson Group PLC lifted its holdings in shares of Lexeo Therapeutics by 15.3% during the 4th quarter. Janus Henderson Group PLC now owns 4,339,254 shares of the company’s stock worth $28,508,000 after acquiring an additional 576,059 shares during the period. Frazier Life Sciences Management L.P. acquired a new stake in Lexeo Therapeutics during the third quarter valued at approximately $11,307,000. Vestal Point Capital LP grew its stake in shares of Lexeo Therapeutics by 41.2% in the 4th quarter. Vestal Point Capital LP now owns 1,200,000 shares of the company’s stock valued at $7,896,000 after purchasing an additional 350,000 shares during the period. Woodline Partners LP raised its holdings in shares of Lexeo Therapeutics by 0.8% in the 4th quarter. Woodline Partners LP now owns 858,691 shares of the company’s stock worth $5,650,000 after buying an additional 6,730 shares in the last quarter. Finally, Verition Fund Management LLC raised its holdings in shares of Lexeo Therapeutics by 84.5% in the 3rd quarter. Verition Fund Management LLC now owns 777,320 shares of the company’s stock worth $7,027,000 after buying an additional 355,928 shares in the last quarter. Institutional investors and hedge funds own 60.67% of the company’s stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.